As pharmas evolve into biopharmas drug company pipelines fill with biopharmaceutical products. Here we will track the latest developments, discoveries and products.
10-Jan-2017 - Kite Pharma has formed a joint venture with Shanghai Fosun Pharmaceutical Industrial Development Company to develop and manufacture its cell therapy axicabtagene ciloleucel in the Chinese market.
09-Jan-2017 - Orchard Therapeutics has selected Dutch CMO PharmaCell to manufacture products from its gene therapy pipeline.
06-Jan-2017 - Shire has confirmed it is selling a former Baxalta manufacturing site in Austria once earmarked for a €138m ($145m) expansion and modernisation.
04-Jan-2017 - The project funded by the UK and Mexican governments will look to prove the scalability of Prokarium’s oral vaccine platform, the firm says.
23-Dec-2016 - Over 30 companies are looking to compete against Abbvie in the adalimumab space. Can you find them all in our word search?
06-Dec-2016 - The development partnership has been extended as GlaxoSmithKline looks to make clinical trial scale batches using Puridify’s Protein A alternative to packed bed chromatography columns.
30-Nov-2016 - An automated system co-developed with Cook Regenetec offers a more controlled and repeatable method of thawing cell and gene therapies than traditional techniques, says Asymptote.
30-Nov-2016 - Thermo Fisher has bolstered its stem cell technology and reagent business through the acquisition of MTI-GlobalStem.
29-Nov-2016 - WuXi Biologics will make a recombinant soluble LAG-3 protein on behalf of Prima Biomed from its 28,000L single-use facility in China set to open next year.
28-Nov-2016 - Plans to build a five-story biomanufacturing plant in Ireland could be shelved following the clinical failure of Pfizer's proposed cholesterol-lowering candidate bococizumab.
18-Nov-2016 - Bristol-Myers Squibb has shaped its manufacturing network to support a pipeline consisting of around 75% biological products, the firm says.
16-Nov-2016 - Gene therapy firm uniQure will consolidate its global manufacturing and cut up to 60 jobs in a bid to recue operating expenses.
15-Nov-2016 - Baylor College of Medicine has extended a partnership to develop off-the-shelf allogeneic cell therapies for Cell Medica.
09-Nov-2016 - Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development
04-Nov-2016 - Germany’s Merck has refused to comment on rumours it is looking to sell its biosimilars business, but what would a hypothetical buyer actually get?
04-Nov-2016 - Shire says it is closing a plasma fractionating facility in Los Angeles, US but remains positive it can successfully manage its post-Baxalta manufacturing network of 17 sites.
14-Oct-2016 - Japan’s early approval process for cell and gene therapies still suffers from clinical recruitment challenges and a solid manufacturing framework, says regenerative medicine group FIRM.
11-Oct-2016 - EpimAb Biotherapeutics will combine its bispecific antibody generating technology with Kymab’s mouse mAb production platform in a cross-licensing deal between the two firms.
06-Oct-2016 - Lonza and Boehringer-Ingelheim dominate the consolidated biologics CMO space but disposable technologies and improved yields are beginning to change this, says PharmSource’s Jim Miller.
27-Sep-2016 - Bluebird Bio’s beta thalassemia gene therapy LentiGlobin has been accepted into the EMA’s priority review programme, PRIME.
21-Sep-2016 - Brexit will not stifle interest in the UK’s cell and gene therapy space, says the CGT Catapult which has reported a tenfold growth in investment since 2012 to £400m ($520m).
20-Sep-2016 - GE Healthcare is in discussions with companies looking to buy four fully-equipped ‘off-the-shelf’ facilities as part of a €150m investment into a biomanufacturing campus in Ireland.
16-Sep-2016 - Since 2011, Samsung Biologics has built two plants, gained Bristol-Myers Squibb and Roche as clients and launched an IPO. With a third facility under construction, Biopharma-Reporter visited to see the...
13-Sep-2016 - Mammalian cell line developer Selexis has signed a fourth licensing agreement in as many months and is planning a "major expansion" early next year ahead of anticipated demand....
06-Sep-2016 - Swedish antibody developer BioInvent is growing its capabilities and has extended a contract with an undisclosed Big Pharma firm.